Therapeutic effect of Xiakucao Oral Liquid combined with 131I on Graves disease
10.7501/j.issn.0253-2670.2019.11.024
- Author:
Min FAN
1
Author Information
1. Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University
- Publication Type:Journal Article
- Keywords:
131I;
Graves;
TGAb;
TPOAb;
TRAb;
Xiakucao Oral Liquid
- From:
Chinese Traditional and Herbal Drugs
2019;50(11):2665-2669
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the therapeutic effect of Xiakucao Oral Liquid combined with 131I on Graves disease and its effect on antibodies. Methods: The efficacy of 96 patients with Graves disease treated with Xiakucao Oral Liquid and 131I (observation group) was compared with those only treated with 131I (control group). The levels of TRAb, TGAb, and TPOAb were compared between the two groups before and after treatment. Results: The efficacy after 6 months of treatment between the observation group and the control group was statistically different (P < 0.05). There were no significant differences in the levels of TRAb, TGAb, and TPOAb before the treatment between the two groups (P > 0.05). The TRAb level in the observation group decreased significantly after 6 months, and the difference between two groups was statistically significant (P < 0.01). The levels of TGAb and TPOAb increased in the two groups after 6 months of treatment, especially in the control group, and the differences were statistically significant (P < 0.05). Conclusion: Xiakucao Oral Liquid combined with 131I can effectively reduce the levels of serum TRAb, TGAb, and TPOAb in patients with Graves disease, and the efficacy of Xiakucao Oral Liquid combined with 131I is significantly better than 131I treatment only.
